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Previewsthis regard, the angle of interaction
between TCR ab heterodimer and pMHC
will affect the torque and, hence, physical
force placed on the CD3 subunits. Catch
bonds may form under load, and these
could also change the nature of TCR-
pMHC interaction.
Lastly, unlike antibody Fabs, the TCR
ab and CD3g and CD3d elements are
highly N-linked glycosylated. Glycans
are dynamic, large, and tunable. Those
adducts will affect movement of the TCR
subunits and subsequent signaling. A
study consistent with this notion shows
that TCR functional avidity is altered by
removal of a Ca glycan, for example (Ku-
ball et al., 2009). Given the detailed infor-
mation available from Adams et al., 42F3
may be an ideal system to explore the
effect of these variables onTcell signaling.
It now appears that MHC-restricted TCR660 Immunity 35, November 23, 2011 ª2011recognition is ‘‘restricted’’ by additional
parameters. The structural and functional
studies in the current paper serve well
to underscore the need for further
investigation.REFERENCES
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It is unclear how an effective T cell repertoire is built from a limited array of T cell receptor (TCR) genes. In this
issue of Immunity, Stadinski et al. (2011) demonstrate that TCR variable (V) a chains can indirectly affect
Vb-mediated recognition of the major histocompatibility complex (MHC) molecule.T cell immunity relies on expression of
a single ab T cell receptor (TCR) within
individual T cells. TCRs are antigen recep-
tors that recognize peptide fragments
complexed to either the major histocom-
patibility complex (MHC) class I or class II
glycoproteins (pMHC). TCRs are derived
from random rearrangement of a limited
set of variable (V), diversity (D), and junc-
tional (J) or of the V and J gene segments
found in the TCRb and TCRa gene loci,
respectively. Regions of hypervariability,
called complementary determining re-
gions (CDR) regions, are encoded within
the Va and Vb chain and form the
antigen-binding site. Moreover, the same
set of TCR gene segments are used to
recognize MHC-like molecules such asCD1 family members. During T cell devel-
opment, only those T cell precursors
expressing a TCR capable of interacting
with self-MHC molecules develop into
mature T cells, a process called positive
selection. This process ensures that
T cells become specific for a particular
MHC class with mature CD8+ and CD4+
T cells typically restricted to MHC class I
(MHC I) and class II (MHC II), respectively.
A long-standing paradox has been just
how does the limited set of available
TCR genes within the genome combine
to generate a T cell repertoire diverse
enough to enable recognition of the
seemingly infinite array of highly polymor-
phic MHC alleles and bound peptide
within an outbred population? This ques-tion has dogged the field for decades
and has been compounded by the struc-
tural data, whereby TCRs can bind the
pMHC in a variety of ways (Burrows
et al., 2010). Recent studies have revisited
this central question and determined that
some closely related MHC II-restricted
TCRs, all of which express the same
TCR Vb8.2 gene, make similar contacts
with their cognate pMHC (reviewed by
Marrack et al., 2008). These studies indi-
cate that MHC restriction might be pre-
determined within the germline TCR
V-region repertoire via conserved interac-
tions between CDR2b germline-encoded
residues that direct MHC binding.
As the adage goes, rules are meant

















Figure 1. Va-Mediated Conformational Adjustments in the Vb Chain
MHC II a chain (yellow) and b chain (green) presenting a peptide (purple) to the abTCR. The TCRb chain
is in light blue, paired with two different TCRa chains (shown in red and pink). The two TCR Va chains
interact with different features of the pMHC II. Moreover, alternate Va chain usage causes a change in
the conformation of the common Vb chain that enables the Vb chain to recognize a different region of
the same MHC II.
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Previewsestablished by MHC restriction during
T cell development do not always hold
true. In some cases, TCRs can cross-
react with different MHC alleles of the
same or different class. Conformational
changes within the CDR loops, or alterna-
tively the MHC-bound peptide, can en-
gender such cross-reactivity (Gras et al.,
2011). To better understand themolecular
interactions that drive MHC restriction,
recent studies have utilized genetically
modified mice where all the MHC class II
molecules express a single pMHC com-
plex (Huseby et al., 2005; Yin et al.,
2011). Despite being MHC class II
restricted, many of the mature CD4+
T cells are now capable of recognizing
mismatched MHC classes (Huseby
et al., 2005; Yin et al., 2011). For example,
an MHC class II-restricted TCR, termed
YAe62.8, exhibits broad cross-reactivity
against both MHC class I and class II
molecules. Recently, the ternary struc-
tures of YAe62.8 complexed with both
the original cognate pMHC II complex
(IAb-3K) and a cross-reactive pMHC I
complex (Kb-pWM) were determined (Yin
et al., 2011). This pioneering study re-
sulted in two major findings. First, thedual pMHC specificity of the YAe62.8
TCR stems from pMHC-induced adjust-
ments in abTCR chain interactions. This
flexibility in the TCR enables CDR loop
reorganization required for Kb-pWM
recognition. Second, despite this struc-
tural reorganization, there is conservation
of specific CDR2b contacts on both MHC
classes. Thus, conservation of these
germline TCR V region contacts, irrespec-
tive of the MHC, can potentially explain
how a particular TCR V region can simi-
larly dock onto multiple MHC molecules.
Given that this contortion in a TCR
structure enables recognition of different
classes of pMHC molecules, a major
question arising is how then does a partic-
ular TCR become MHC specific? Making
further use of the YAe68.2 model system,
in this issue of Immunity, Stadinski et al.
(2011) addressed this question and
demonstrated that the intrinsic ‘‘cross-
talk’’ between the a and b chains can be
an important factor in determining MHC
specificity (Figure 1). The authors gener-
ated mice that expressed the IAb-3K-
specific TCR Vb8.2 YAe62.8 chain as
a single transgene (termed YAe62
b mice). These mice were then crossedImmunity 35, Nonto mice that expressed both wild-type
MHC class I and II (MHCwt), lacked MHC
class II but not MHC class I (MHC class
II-deficient), or lacked both MHC class I
and II (as well as other nonconventional
MHC; MHCnull). Unsurprisingly, IAb-3K-
specific YAe62 b T cells were exclusively
selected into the CD4+ compartment
within MHCIwt mice. In MHC II-deficient
mice, IAb-3K-specific, YAe62 b T cells
were observed in both the CD4+ and
CD8+ compartments. Thus, exclusive
selection onMHCclass I resulted in apop-
ulation of MHC-cross-reactive T cells
whereas selection in the presence of
both MHC class I and II resulted in a
MHC-specific T cell population.
Partitioning of MHC-specific and MHC-
cross-reactive IAb-3K T cell populations
segregated with differences in TCR Va
chain pairing with the YAe62 b TCR. In
MHCwt mice, IAb-3K-reactive, MHC-
specific CD4+ T cells exhibited preferred
Va2 gene segment usage. In contrast,
Va11 was utilized by the IAb-3K-specific
but MHC-cross-reactive CD4+ T cells. A
lack of Va11 usage within IAb-3K-reactive
CD4+ T cells from MHCwt mice suggests
that MHC class II expression drives nega-
tive selection of these cross-reactive
T cells. This observation supports a
previous notion that negative selection
trims MHC-cross-reactive T cells from
the developing repertoire, ensuring MHC
restriction (Huseby et al., 2005).
In this particular example, the TCR Va-
dependent alterations in the partner TCR
Vb interactions dictates whether a TCR
will be MHC restricted or MHC cross-
reactive. Analysis of MHC contacts for
either MHC-specific (Va2+YAe62 b+ from
MHCwt mice) or MHC-cross-reactive
(Va11+YAe62 b+ from MHC-II-deficient
mice) TCRs showed that Va2pairing alters
the YAe62 b chain CDR2b chain contacts
with theMHC a helix. Thus, simply altering
TCR Va pairing was sufficient to convert
MHC-cross-reactive TCRs into MHC-
restricted TCRs. Structural comparison
of the original Va4-Vb8.2 YAe62.8 TCR
and a newly identified Va2-Vb8.2 YAe62
b TCR (termed J809.B5), both complexed
to IAb-3K, highlighted even more differ-
ences between MHC-cross-reactive and
MHC-restricted TCRs. Despite sharing
the same TCR Vb8.2 chain, the MHC-
restricted J809.B5 Va2 made extensive
contact with the bound peptide and
altered the germline Vb8.2 contacts withovember 23, 2011 ª2011 Elsevier Inc. 661
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Previewsthe MHC. In contrast, the YAe62.8 Va4
was more MHC focused. Thus, Va2 pair-
ing enables MHC binding interactions
that promote MHC restriction, rather
than cross-reactivity.
An implication from this study is the
notion that a common set of conserved
pairwise interactions between a given
TCR V region and the bound MHC
controls MHC restriction is not completely
accurate. Indeed, this ‘‘codon’’ concept
initially arose after sampling a limited
array of TCR Vb8.2 chains that pair with
related TCR Va chains (Marrack et al.,
2008). The study by Stadinski et al.
(2011) now shows differing interactions
with the same Vb8.2 chain, and moreover
Vb8.2 TCRs have been shown to dock
differently onto the nonclassical MHC I
molecule, CD1d (Pellicci et al., 2009).
This current study has shown that the
difference between a MHC-restricted
and MHC-cross-reactive TCR can be as
simple as alternative TCR Va pairing influ-
encing where specific TCR Vb residues
land on the peptide-MHC complex. Inter-
estingly, this may explain an observation
that despite sharing the same TCR Vb
chain, differences in specific TCR Va pair-
ing alters the MHC restriction of a human
virus-specific CD8+ T cell repertoire (Miles
et al., 2006).
There has been at least one report of
MHC class cross-recognition where
human leukocyte antigen (HLA)-Cw
0602-restricted CD8+ T cells, specific for
a cytomegalovirus virus antigen, can
recognize the MHC class II HLA-DR4
molecule (Rist et al., 2009). Importantly,
MHC-specific versus MHC-cross-reac-
tive responses segregate with preferred662 Immunity 35, November 23, 2011 ª2011TCR Vb usage and exhibit different
requirements for pMHC recognition.
Thus, the findings of Stadinski et al.
(2011) may be more generalizable. In
a transplant setting, understanding the
rules that govern MHC class cross-reac-
tivity may lead to better predictors of
whether pre-existing MHC-restricted
T cell repertoires may recognize other
MHC classes present on donor tissue.
Another important implication is the
need to re-evaluate, in some cases, the
mechanism of preferred TCR bias within
antigen-specific repertoires. Preferred
TCR V-region usage is a hallmark of
many pathogen-specific T cell immune
repertoires. A recent study established
that the preferred TCR bias associated
with immune T cell repertoires already
exists within naive, antigen-specific
T cell repertoires (La Gruta et al., 2010).
This suggests that T cell selection events
must in some way shape observed TCR
bias prior to pathogen encounter. The
data presented by Stadinski et al. (2011)
suggest TCR bias within the naive,
antigen-specific repertoires may reflect
constraints imposed by the positive and
negative selection events that help
prevent MHC cross-reactivity.
We thought we were starting to under-
stand the molecular basis of TCR bias
within immune repertoires and the basis
of what dictates the conserved orientation
of TCRs interacting with MHC molecules.
It is clear from this study that there is still
much to learn about the rules that govern
TCR-pMHC interactions. Just as a new
hypothesis appears to be holding ground,
a set of new findings means we have to
re-evaluate what it takes for TCR-medi-Elsevier Inc.ated recognition of pMHC. It proves that
when we think we have worked out how
TCRs see their antigen, TCRs can still
come out swinging and continue to pro-
vide new solutions to the problem of
MHC restriction.REFERENCES
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